<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562809</url>
  </required_header>
  <id_info>
    <org_study_id>L_8829</org_study_id>
    <nct_id>NCT00562809</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension</brief_title>
  <official_title>A Multicenter, Open-Label Study Assessing the Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Hypertension Not Controlled by Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Irbesartan 150/12.5 mg and
      300/25 mg in patients with hypertension not controlled by monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary and secondary endpoints applied to sub-groups defined by age, race, diabetes,
      metabolic syndrome and prior HTN therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the mean SBP</measure>
    <time_frame>from baseline to week 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean DBP</measure>
    <time_frame>from baseline to week 18.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mean SBP and DBP</measure>
    <time_frame>from baseline to week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP and DBP response and control rates</measure>
    <time_frame>at weeks 10 and 18</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1005</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IRBESARTAN</intervention_name>
    <description>150/12.5 mg tablets one or two tablets orally per day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have hypertension and uncontrolled SBP on monotherapy.

          -  Patients who have read, signed and received a copy of the informed consent prior to
             any study procedures

        Note: Female patients must be post-menopausal for one year, surgically sterilized, or using
        a medically accepted method of contraception (intrauterine device, oral contraceptives,
        barrier method with spermicide) and must agree to use an effective method of contraception
        throughout the study.

        Exclusion Criteria:

          -  Any history of secondary hypertension

          -  History of hypertensive encephalopathy, stroke, or transient ischemic attack (TIA)
             within the past 12 months

          -  History of myocardial infarction, percutaneous transluminal coronary
             revascularization, coronary artery bypass graft, and/or unstable angina pectoris
             within the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Mooney</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2007</study_first_posted>
  <last_update_submitted>November 26, 2007</last_update_submitted>
  <last_update_submitted_qc>November 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

